Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing’s sarcoma

Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna 40136, Italy.
European Journal of Cancer (Impact Factor: 5.42). 02/2006; 42(1):91-6. DOI: 10.1016/j.ejca.2005.09.015
Source: PubMed


CD99 is a 32kDa surface glycoprotein that is involved in the migration of leukocytes, cell-cell adhesion and apoptosis of T cells and Ewing's sarcoma (ES) cells, two cell types with a high level of CD99 expression. Engagement of the molecule induces a rapid death signal that appears to be related to the level of expression of this antigen. The rapid apoptosis induced by agonistic anti-CD99 monoclonal antibodies is of clinical interest in ES, a tumour for which no new drugs have been described as clearly effective in the last 10 years. In this study, we show that an anti-CD99 monoclonal antibody can be used to advantage in association with doxorubicin. Striking effectiveness was observed against local tumours and metastases. No remarkably toxic effects of anti-CD99 monoclonal antibody were found in bone marrow against blood precursors. These results provide the necessary rationale and support for a novel modality of therapeutic intervention, which may have application in the care of patients with ES.

Download full-text


Available from: Giordano Nicoletti,
  • Source
    • "HSPs are chaperone proteins that help to maintain protein stability, renature unfolded proteins, or target their degradation [117, 118]. Several of these HSP client proteins are involved in signal transduction pathways that lead to proliferation, apoptosis, or cell cycle progression in several cancers, which is precisely the case for IGF1R [119, 120]. Therefore, HSP inhibition is a therapeutic strategy to inhibit multiple receptor pathways. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Rhabdomyosarcomas (RMS) are a heterogeneous group of tumors that share features of skeletal myogenesis and represent the most common pediatric soft tissue sarcoma. Even though significant advances have been achieved in RMS treatment, prognosis remains very poor for many patients. Several elements of the Insulin-like Growth Factor (IGF) pathway are involved in sarcomas, including RMS. The IGF2 ligand is highly expressed in most, if not all, RMS, and frequent overexpression of the receptor IGF1R is also found. This is confirmed here through mining expression profiling data of a large series of RMS samples. IGF signaling is implicated in the genesis, growth, proliferation, and metastasis of RMS. Blockade of this pathway is therefore a potential therapeutic strategy for the treatment of RMS. In this paper we examine the biological rationale for targeting the IGF pathway in RMS as well as the current associated preclinical and clinical experience.
    Sarcoma 03/2011; 2011(10):209736. DOI:10.1155/2011/209736
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BackgroundAlthough cure rates for childhood cancer have improved from below 20% to more than 75% during the last 40years, childhood cancer is still the number one killer amongst paediatric diseases. European paediatric cancer research also faces new challenges by the increasing number of childhood cancer survivors, some of whom experience significantly altered life-quality due to serious psychosocial and medical long-term side-effects of the intensive cancer treatment. Hence, to achieve even higher quantity and quality of cure for Europe’s children and adolescents with cancer, development of new treatment options is now required, as are intensified epidemiological investigations into health and psycho-social issues of paediatric cancer survivors on the EU-level. MethodsBased on presentations and discussions at a recent meeting of leading European paediatric oncologists supported by the EC-funded science-communication project “DIRECT", this article discusses the situation of European paediatric cancer research under the EU-Framework Programmes (FPs). ResultsSingle, partially interlinking paediatric oncological research projects received EU-funding during the last three FPs. However, given the increased budgets for health research under the FP6 and FP7 together with their goal to improve the European Research Area (ERA), relatively few of the current challenges in European paediatric oncology have been covered so far when compared to the spending for adult cancer. ConclusionAlthough still fragmented, current EC-funded projects in paediatric oncology would be amenable to a higher level of integration. In order to achieve a closer approach to “total cure” including all medical, psychological and social aspects, paediatric cancer should become a horizontal priority of European research funding.
    memo - Magazine of European Medical Oncology 12/2010; 2(4):246-254. DOI:10.1007/s12254-009-0169-8
  • [Show abstract] [Hide abstract]
    ABSTRACT: When connective tissue undergoes malignant transformation, glioblastomas and sarcomas arise. However, the ancient biochemical mechanisms, which are now operational in sarcomas distorted by mutations and gene fusions in misaligned chromosomes, were originally acquired by those cells that emerged during the Cambrian explosion. Preserved throughout evolution up to the genus Homo, these mechanisms dictate the apoptosis- and senescence-resistant immortality of malignant cells. A 'retroviral paradox' distinguishes human sarcomas from those of the animal world. In contrast to the retrovirally induced sarcomatous transformation of animal (avian, murine, feline and simian) cells, human sarcomas have so far failed to yield a causative retroviral isolate. However, the proto-oncogenes/oncogenes transduced from their host cells by retroviruses of animals are the same that are active in human sarcomas. Since the encoded oncoproteins arise after birth, they are recognized frequently by the immune system of the host. Immune lymphocytes that kill autologous sarcoma cells in vitro commonly fail to do so in vivo. Sarcoma vaccines generate immune T- and natural killer cell reactions; even when vaccinated patients do not show a clinical response, their tumors become more sensitive to chemotherapy. The aim of this review is to lay a solid molecular biological foundation for the conclusion that targeting the sarcoma oncogenes will result in regression of the disease.
    Expert Review of Anti-infective Therapy 02/2007; 7(1):31-56. DOI:10.1586/14737140.7.1.31 · 2.25 Impact Factor
Show more